跳到正文
原文
Endpoints News· @endpts · X·· 18 天前AI 评分42
AI 导读

Actio Biosciences 将其遗传学驱动的罕见病管线其余部分分拆至 Setara,后者融资 9000 万美元。https://endpoints.news/setara-gets-90m-to-continue-rare-disease-pipeline-spun-out-of-jazzs-actio-deal/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

正文

Actio Biosciences spun out the rest of its genetics-driven rare disease pipeline into Setara, which raised $90M. https://endpoints.news/setara-gets-90m-to-continue-rare-disease-pipeline-spun-out-of-jazzs-actio-deal/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial

来源:Endpoints News · x.com